ROCHE HOLDING AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 223.8 CHF | -1.78% |
|
+0.50% | -9.04% |
| 02:07pm | ROCHE HOLDINGS AG : UBS remains Neutral | ZD |
| 10:45am | Wegovy weight loss sustained for four years in trial, Novo Nordisk says | RE |
Presenter SpeechChristoph Franz (Executives)Good morning, dear shareholders, ladies and gentle...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
227.8
CHF
Average target price
279.4
CHF
Spread / Average Target
+22.65%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.04% | 203B | |
| +29.98% | 682B | |
| +32.39% | 586B | |
| -3.52% | 364B | |
| +18.59% | 327B | |
| +4.07% | 285B | |
| +16.50% | 240B | |
| +9.56% | 209B | |
| +7.09% | 165B | |
| -1.22% | 161B |
- Stock Market
- Equities
- ROG Stock
- News Roche Holding AG
- Transcript : Roche Holding AG - Shareholder/Analyst Call